IntraGel Therapeutics

INTRAGEL is a research-driven company dedicated to pioneering an advanced treatment for solid tumors using our state-of-the-art gel-based drug delivery technology. The SRGel platform enables local and prolonged release of a wide range of anti-cancer medications offering new life-changing cancer treatment options. The SRGel platform is revolutionizing cancer treatment by enabling local sustained release of anticancer drugs at the tumor site, to maximize therapeutic effectiveness while minimizing systemic exposure and adverse effects. Built on natural and safe fatty acids, its unique hydrophobic, biocompatible and biodegradable gel-based composition is a true breakthrough in drug delivery. As an injectable pre-filled single syringe, SRGel is easy to use, ready to be placed in any solid tumor, including surgically inaccessible tumors and/or chemo/radio-resistant tumors. SRGel has successfully been combined with cisplatin, its flagship product, TumoCure, to treat head and neck, and lung cancer. Other drugs, such as paclitaxel and temozolamide, have also been successfully combined to treat other tumors. Future products in development aim to address other unmet medical needs in, colorectal, ovarian, and testicular cancer.

IntraGel Therapeutics has raised $450K in total funding across 3 rounds. The company is currently at the Seed stage. Key investors include NGT HealthCare II, Israel Innovation Authority , NGT3.

IntraGel Therapeutics was founded in 2020 by Peter Siman (Co-founder & CEO), Avner Geva (Co-founder), Avi Domb (Co-founder).

IntraGel Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Materials & Substances. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

IntraGel Therapeutics is based in Wadi el-Haj Street 13, Nazareth, Israel, North District.